Advertisement

Der Ophthalmologe

, Volume 105, Issue 7, pp 661–668 | Cite as

Intravitreales Triamcinolon und Bevacizumab bei Pigmentepithelabhebung im Rahmen der AMD

  • A. Frimpong-Boateng
  • M.A. Varde
  • F. Rüfer
  • A. Bunse
  • J. Roider
Originalien

Zusammenfassung

Hintergrund

In einer retrospektiven Datenanalyse wurde der Effekt der Vascular-endothelial-growth-factor (VEGF)-Hemmer Triamcinolon und Bevacizumab bei Patienten mit einer serösen Pigmentepithelabhebung (PED) bei altersabhängiger Makuladegeneration (AMD) evaluiert.

Patienten und Methoden

Daten von 45 Patienten (45 Augen) wurden analysiert: 11 Patienten erhielten eine einmalige intravitreale Triamcinolonapplikation, 16 eine einmalige intravitreale Bevacizumabeingabe und die restlichen 18 Patienten erhielten keine Therapie. Der Visus, die relative Höhe der PED, die Netzhautdicke und die zystoide Komponente der Netzhaut wurden nach 6 Monaten Nachbeobachtungszeit evaluiert.

Ergebnisse

Nach intravitrealer Bevacizumabeingabe zeigte über 90% der Patienten eine Visusstabilisierung oder -verbesserung. Nach intravitrealer Triamcinoloninjektion kam es bei 63% der Patienten zu einer Visusstabilisierung. Patienten ohne Therapie zeigten eine signifikante Visusverschlechterung.

Schlussfolgerung

Die vorliegenden Daten deuten auf eine bessere Visusprognose nach intravitrealer Bevacizumabeingabe hin. Die Visusprognose scheint eher von der zystoiden Komponente des Netzhautödems als von der Höhe der PED abhängig zu sein. Um diese Befunde zu verifizieren, sind größere Patientenzahlen und längere Nachbeobachtungszeiten erforderlich.

Schlüsselwörter

Seröse Pigmentepithelabhebung Bevacizumab Triamcinolon Spontanverlauf 

Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD

Abstract

Background

The effect of the vascular endothelial growth factor (VEGF) inhibitors triamcinolone and bevacizumab (Avastin) on serous pigment epithelial detachment (PED) related to age-dependent macular degeneration (AMD) was analysed retrospectively.

Patients and Methods

Data of 45 patients (45 eyes) were evaluated: 11 patients received an intravitreal injection with triamcinolone and 16 with bevacizumab. The remaining 18 patients received no therapy. Visual acuity (VA), height of the PED, retinal thickness and the cystoid component of the PED were compared after 6 months follow-up.

Results

Over 90% showed a stabilisation or improvement in VA after bevacizumab therapy; 63% of those who received triamcinolone showed VA stabilisation. Patients who received no therapy had a significant decrease in VA.

Conclusions

Our data seem to implicate that VA outcome is much better after bevacizumab treatment. VA outcome seems to correlate with the cystoid component of the foveal oedema rather than with the height of PED. A greater number of patients with a longer period of follow-up are necessary to confirm these results.

Keywords

Serous pigment epithelial detachment Bevacizumab Triamcinolone Natural outcome 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363–372PubMedCrossRefGoogle Scholar
  2. 2.
    Berger AS, Kaplan HJ (1992) Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results. Ophthalmology 99: 969–976PubMedGoogle Scholar
  3. 3.
    Bird AC, Marshall J (1986) Retinal pigment epithelial detachments in the elderly. Trans Ophthal Soc U K 105: 674–682Google Scholar
  4. 4.
    Bird AC (1991) Doyne lecture. Pathogenesis of retinal pigment epithelial detachment in the elderly; the relevance of Bruch’s membrane change. Eye 5: 1–12PubMedGoogle Scholar
  5. 5.
    Casswell AG, Kohen D, Bird AC (1985) Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 69: 397–403PubMedCrossRefGoogle Scholar
  6. 6.
    Chan CK, Meyer CH, Gross JG et al. (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27: 541–551PubMedCrossRefGoogle Scholar
  7. 7.
    Chuang EL, Bird AC (1988) The pathogenesis of tears of the retinal pigment epithelium. Am J Ophthalmol 105: 285–290PubMedGoogle Scholar
  8. 8.
    Edelman JL, Lutz D, Castro MR (2005) Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood–aqueous barrier breakdown. Exp Eye Res 80: 249–258PubMedCrossRefGoogle Scholar
  9. 9.
    Ferrara N, Damico L, Shams N et al. (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26: 859–870PubMedCrossRefGoogle Scholar
  10. 10.
    Folkman J, Ingber DE (1987) Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 206: 374–383PubMedCrossRefGoogle Scholar
  11. 11.
    Gass JDM (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63: 573–711Google Scholar
  12. 12.
    Gragoudas ES, Adamis AP, Cunningham ET et al. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805–2816PubMedCrossRefGoogle Scholar
  13. 13.
    Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342PubMedCrossRefGoogle Scholar
  14. 14.
    Jonas JB (2004) Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 137: 560–562PubMedCrossRefGoogle Scholar
  15. 15.
    Jonas JB, Degenring RF, Kreissig I et al. (2005) Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 19: 163–170PubMedCrossRefGoogle Scholar
  16. 16.
    Klein R, Klein BEK, Linton KLP (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99: 933–943PubMedGoogle Scholar
  17. 17.
    Kliffen M, Sharma HS, Mooy CM et al. (1997) Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81: 154–162PubMedGoogle Scholar
  18. 18.
    Krzystolik MG, Afshari MA, Adamis AP et al. (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120: 338–346PubMedGoogle Scholar
  19. 19.
    Lopez P, Sippy B, Lambert H et al. (1996) Transdifferential retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37: 855–868PubMedGoogle Scholar
  20. 20.
    Machemer R, Steinhorst UH (1993) Retinal separation, retinotomy and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 231: 635–641PubMedCrossRefGoogle Scholar
  21. 21.
    Macular Photocoagulation Study Group (1991) Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 109: 1242–1257Google Scholar
  22. 22.
    Meyer CH, Toth CA (2001) Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature. Graefes Arch Clin Exp Ophthalmol 239: 325–333PubMedCrossRefGoogle Scholar
  23. 23.
    Moorfields Macular Study Group (1982a) Retinal pigment epithelial detachments in the elderly: a controlled trial argon laser photocoagulation. Br J Ophthalmol 66: 1–16CrossRefGoogle Scholar
  24. 24.
    Moorfields Macular Study Group (1982b) Treatment of senile disciform macular degeneration: a single-blind randomized trial by argon laser photocoagulation. Br J Ophthalmol 66: 745–753CrossRefGoogle Scholar
  25. 25.
    Pece A, Introini U, Bottoni F, Brancato R (2001) Acute retinal pigment tear after photodynamic therapy. Retina 21: 661–665PubMedCrossRefGoogle Scholar
  26. 26.
    Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36: 331–335PubMedGoogle Scholar
  27. 27.
    Schindler RH, Chandler DB, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93: 415–417PubMedGoogle Scholar
  28. 28.
    Singerman LJ (1988) Laser photocoagulation for choroidal new vessel membrane complicating age-related macular degeneration associated with pigment epithelial detachment. Retina 8: 115–121PubMedCrossRefGoogle Scholar
  29. 29.
    Spilsbury K, Garrett KL, Shen WY et al. (2000) Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 157: 135–144PubMedGoogle Scholar
  30. 30.
    Steinberg RH, Miller SS (1979) Transport and membrane properties of the retinal pigment epithelium. In: Zinn KM, Marmor MF (eds) The retinal pigment epithelium. Harvard University Press, Cambridge MA, pp 205–225Google Scholar

Copyright information

© Springer Medizin Verlag 2008

Authors and Affiliations

  • A. Frimpong-Boateng
    • 1
  • M.A. Varde
    • 1
  • F. Rüfer
    • 1
  • A. Bunse
    • 1
  • J. Roider
    • 1
  1. 1.AugenklinikUniversitätsklinikum Schleswig-Holstein, Campus KielKielDeutschland

Personalised recommendations